Pyxis Oncology Appoints Thomas Civik as Interim CEO
Pyxis Oncology announced a leadership transition. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the company's IPO and a biotechnology executive, has been appointed Interim CEO, effective immediately. Lara Sullivan has stepped down from her roles as President, CEO and CMO. The company's established clinical development leadership team will continue to execute ongoing trials and operational priorities without interruption. In parallel, the Board of Directors has initiated a structured search for a permanent CEO. Civik most recently served as President and CEO of Five Prime Therapeutics, where he led the company through its acquisition by Amgen for $1.9B in April 2021. Prior to Five Prime Therapeutics, he was Chief Commercial Officer at Foundation Medicine. He most recently served as Chairperson of the Board of ImCheck Therapeutics and Repare Therapeutics. Earlier in his career, Civik spent 17 years at Genentech.
